(A) PFS and (B) OS for all patients treated with lenalidomide-bortezomib-dexamethasone (censoring at time of transplant, n = 5). Estimated 6-, 12-, and 24-month PFS rates were 75% (95% CI, 62-84), 36% (95% CI, 24-48), and 15% (95% CI, 7-25), respectively. Estimated 12- and 24-month OS rates were 89% (95% CI, 77-84) and 65% (95% CI, 51-76), respectively.